✓ Translated by DotMD AI Clinical Council Source: International journal of hematology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38888812 ↗

Phase III Randomized Trial: Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study (N = 13)

Original Paper Title: “Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 13
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings.
  • Study Design & Sample: Phase III Randomized Trial published in International journal of hematology (N = 13 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in International journal of hematology (2024), this phase iii randomized trial evaluating 13 human participants investigated: Asciminib is a first-in-class BCR::ABL1 inhibitor that Specifically Targets the ABL1 Myristoyl Pocket (STAMP). Key clinical takeaway: Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (International journal of hematology, 2024-09-15; N = 13; Rigor 82/100): Despite the longer duration of exposure to asciminib, its safety and tolerability continued to be favorable with no new or worsening safety findings.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: bosutinib → Condition: bladder-neurogenic → Condition: hydronephrosis →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38888812: Phase III Randomized Trial: Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study (N = 13)

3 of 3 Free Questions Remaining